Physician profile
Aaron B Glass
NPI 1871741157
$1,580.11
in general payments reported to CMS, 2019-2025
12 companies · $366 in 2025
The $366 reported for 2025 was more than what 78% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $144 · 2021: $171 · 2022: $125 · 2023: $377 · 2024: $238 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Entertainment: $23.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.74 |
| Entertainment | $23.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $670.33 | 2019-2025 | Precision7, Precision 1, Hydrus Microstent |
| Coopervision INC. | $454.04 | 2021-2025 | Myday Contact Lens |
| Oyster Point Pharma, INC. | $119.41 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $74.31 | 2019-2022 | |
| Optos, INC. | $66.73 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $50.08 | 2020-2024 | |
| Bausch & Lomb Americas INC. | $49.09 | 2023-2025 | Xiidra, Miebo |
| Dompe US, INC. | $26.32 | 2021 | |
| Kala Pharmaceuticals, INC. | $21.94 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.58 | 2020 | |
| Notal Vision, INC. | $14.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.23 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Glass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.